Supportive Care Articles | Page 2

FDA Eliminates REMS Requirement for ESAs
The FDA has eliminated the need for risk evaluation and mitigation strategy certification prior to the administration of erythropoiesis-stimulating agents for anemia due to myelosuppressive chemotherapy.
FDA Accepts Ibrutinib Application for GVHD
The FDA has accepted a supplemental new drug application for ibrutinib as a treatment for patients with chronic graft-versus-host-disease after failure of 1 or more lines of systemic therapy.
FDA Approves Telotristat Ethyl for Carcinoid Syndrome Diarrhea
The FDA has approved telotristat ethyl (Xermelo) for use in combination with somatostatin analog (SSA) as a treatment for carcinoid syndrome diarrhea in patients with metastatic neuroendocrine tumors that cannot be adequately controlled by SSA therapy alone.
Rolapitant Recommended for EU Approval for CINV
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of oral rolapitant (Varuby; Varubi in US) for the prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy.
Prophylactic Letermovir Limits CMV Infections Post-Transplantation
Prophylactic treatment with letermovir lowered the rates of cytomegalovirus infection and all-cause mortality compared with placebo for CMV-seropositive patients following an allogeneic hematopoietic stem cell transplant.
High-User Focus Trims Oncology Tab
It was 15 years ago that Jeffrey Brenner, MD, hypothesized that patients with the highest costs in the Camden, New Jersey, healthcare system received the worst care.
Findings from the first prospective, randomized clinical trial to evaluate modern scalp-cooling demonstrate that the system is safe and effective in reducing hair loss in women being treated with chemotherapy for their breast cancer, especially for those on taxane-based regimens.
It's Time to Take Action on Quality Improvement Measures
In 2014, under the leadership of UVA Executive Vice President Richard P. Shannon, MD, the Be Safe initiative was developed to deliver the highest-quality of advanced healthcare to patients, and emphasizes 3 main areas.
For patients receiving highly emetogenic chemotherapy, olanzapine (Zyprexa) was found to demonstrate a significant improvement in the prevention of nausea when it was added to a standard antiemetic regimen.
Psychological Effects From ADT a Growing Challenge in Prostate Cancer
Heather Jim, MD, describes the psychological impacts of testosterone-lowering drugs for patients with prostate cancer—and what oncologists should do to help.
Publication Bottom Border
Border Publication
x